Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody

Cancer Communications

article

Jiwei Huang¹  Yueming Wang¹  Haoran Zhang³  Xiaoyi Hu⁴  Ping Wang⁵  Wen Cai⁶  Yichu Yuan⁶  Hao Zeng³  Jin Zhang¹  Wen Kong¹  Yiran Huang¹  Shuo Wang⁵  Jianming Guo⁴  Qiang Wei³  Wei Xue¹ 

[1] Department of Urology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University;These authors have contributed equally to this work.;Department of Urology, West China Hospital, Sichuan University;Department of Urology, Zhongshan Hospital, Fudan University;Department of Urology, First Affiliated Hospital, Zhejiang University School of Medicine;Department of Urology, Second Affiliated Hospital, Zhejiang University School of Medicine

DOI  :  10.1002/cac2.12206

学科分类：社会科学、人文和艺术（综合）

来源: Springer

【 摘 要 】

The prognosis of metastatic renal cell carcinoma(mRCC) has been significantly improved with the development and widespread use of vascular endothelial growthfactor (VEGF) pathway inhibitors and mammalian targetof rapamycin (mTOR) pathway inhibitors [1]. For the pastdecade, the standard of care utilized in the first-line setting was VEGF-targeted therapies. Recently, the mRCCtreatment landscape has rapidly changed with the exploration of combinations of immune checkpoint inhibitors(ICIs) and anti-VEGF agents [2,3]. The Keynote-426 trialdemonstrated both progression-free survival (PFS) andoverall survival (OS) advantages of axitinib plus pembrolizumab over sunitinib for untreated advanced RCCpatients [2]. Based on these results, axitinib plus pembrolizumab, cabozantinib plus nivolumab, lenvatinib pluspembrolizumab, and nivolumab plus ipilimumab havebeen recommended as first-line treatment in recent guidelines.

【 授权许可】

CC BY|CC BY-NC-ND